-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
Muscle Atrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscle Atrophy - Drugs In Development, 2023’, provides an overview of the Muscle Atrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thromboangiitis obliterans (Buerger disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Thromboangiitis obliterans (Buerger disease) - Drugs In Development, 2023’, provides an overview of the Thromboangiitis obliterans (Buerger disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thromboangiitis obliterans (Buerger disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Vasculitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Vasculitis - Drugs In Development, 2023’, provides an overview of the Vasculitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GH-55 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GH-55 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GH-55 in Solid Tumor Drug Details: GH-55 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Curcumin + Doxorubicin) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Curcumin + Doxorubicin) in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Curcumin + Doxorubicin) in Solid Tumor Drug Details: Imx-110...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utidelone in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utidelone in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utidelone in Solid Tumor Drug Details: Utidelone is an microtubule stabilizing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utidelone in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utidelone in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utidelone in Triple-Negative Breast Cancer (TNBC) Drug Details: Utidelone...